Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Geode Capital Management LLC increased its position in Verastem, Inc. (NASDAQ:VSTM – Free Report) by 67.6% during the third ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

RBC Capital raised the firm’s price target on Verastem (VSTM) to $16 from $13 and keeps an Outperform rating on the shares as part of a broader ...

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...

BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...